Fortify, a Phase 1b indication expansion trial of Pln-101095, continues strong enrollment Pliant s proprietary selective, targeted, integrin-mediated delivery platform demonstrates encouraging initial preclinical results
Why Is Pliant Therapeutics, Inc. (PLRX) Stock Down Today?
Updated Nov 21, 2026 5:15 AM ET · Prev Close $0.62
Session Regime & Catalyst Assessment
68% Signal ConvictionPliant Therapeutics, Inc. Pulling Back 4.02% on 2.10x Relative Volume
Pliant Therapeutics, Inc. (PLRX) is pulling back 4.02% (-$0.02) to $0.60 on 2.10x average session volume. Relative to benchmarks, PLRX is trading in line with the S&P 500 (-0.38% alpha). 14-day RSI stands at 15.5, keeping momentum in a oversold regime.
Fortify, a Phase 1b indication expansion trial of Pln-101095, continues strong enrollment Pliant s proprietary selective, targeted, integrin-mediated delivery platform demonstrates encouraging initial preclinical results
Price ($0.60) trades relative to 20-day SMA ($0.78) and 50-day SMA ($0.92).
Market & Sector Relative Strength
PLRX trading in line with the S&P 500 (-0.38% alpha)Recent PLRX Catalyst Headlines
Verified WireSouth San Francisco, Calif., Nov. 09, 2026 Globe Newswire -- Pliant Therapeutics, Inc. Nasdaq PLRX , today announced the presentation of preclinical proof-of-concept data and new clinical biomarker analyses related to PL
South San Francisco, Calif., Oct. 29, 2026 Globe Newswire -- Pliant Therapeutics, Inc. Nasdaq PLRX , a clinical-stage biotechnology company focused on the discovery and development of integrin-based therapeutics, today a
Craig D. Blanchette, Ph.D. Dr. Blanchette is a recognized leader in RNAi drug discovery and development was appointed Senior Vice President, Research siRNA of Pliant Therapeutics. Recognized leader in RNAi drug discovery
1–3 Day Expected Range & Key Level
54% Follow-ThroughMonitor volume expansion above 1.5x RVOL around $0.57 (session support) for directional breakout confirmation.
Technical Regime (PLRX)
BEARISH MA TRENDRetail & Crowd Sentiment
BearishA bullish trader on StockTwits expressed excitement about $PLRX, asking why the stock isn't gaining more attention as a potential next runner.
About Pliant Therapeutics, Inc.
Pliant Therapeutics Inc is a clinical-stage biopharmaceutical company focused on discovering and developing novel therapies for the treatment of fibrosis and related diseases. Its primary product candidate is bexotegrast (Pln-74809), an oral, small molecule, that the company is developing for the treatment of idiopathic pulmonary fibrosis, or IPF, and primary sclerosing cholangitis.
Get Instant PLRX Catalyst Alerts
Receive an email alert when PLRX triggers an unusual volume breakout, options sweep, or rating shift.
Other Liquid Stocks Moving Today
All Today's MoversPLRX Session & Catalyst FAQ
Why is PLRX stock down today?
Pliant Therapeutics, Inc. (PLRX) is pulling back 4.02% (-$0.02) to $0.60 on 2.10x average session volume. Relative to benchmarks, PLRX is trading in line with the S&P 500 (-0.38% alpha). 14-day RSI stands at 15.5, keeping momentum in a oversold regime.
Is PLRX stock a buy or sell right now?
Today's session carries a 68% catalyst conviction score on 2.10x relative volume (high participation). Our multi-factor model currently rates PLRX as HOLD. Review full valuation, quality, and timing signals on the PLRX Buy or Sell Decision Brief →
What is PLRX's intrinsic value and expected trading range?
At $0.60, PLRX's modeled 1-to-3 session range is $0.57 – $0.63, with a key inflection level at $0.57 (session support). Compare current price against multi-year cash flow projections in the PLRX Intrinsic Value & DCF Model → and Market Cycle Phase Tracker →
What do RSI and moving averages signal for PLRX?
RSI at 15.5 indicates oversold conditions — watch for mean-reversion support. PLRX trades at $0.60 relative to its 20-day SMA ($0.78) and 50-day SMA ($0.92), reflecting a bearish moving-average structure.
Tradestie Flagship Research & Market Hubs
Live institutional catalyst tape ranking liquid gainers, losers, options sweeps, and RVOL surges.
Track spot H100/B200 compute rental rates and frontier LLM inference token economics.
Wafer yield, CoWoS packaging, and HBM bill-of-materials teardown models across AI accelerators.
Monitor engineering velocity and upstream foundry wafer demand inflections across tech leaders.
Live conviction tracking, invalidation guardrails, and thesis health checks on flagship ideas.
Backtest-validated unusual options positioning and open-interest accumulation setups.
Daily ranked quantitative leaderboard with audited forward-return track record vs S&P 500.
High-yield, quality-screened cash-secured put and put-spread income candidates.